AMF Tjanstepension AB Has $20.85 Million Stock Holdings in Cencora, Inc. $COR

AMF Tjanstepension AB trimmed its position in Cencora, Inc. (NYSE:COR) by 40.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,701 shares of the company’s stock after selling 45,942 shares during the period. AMF Tjanstepension AB’s holdings in Cencora were worth $20,846,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in COR. Vanguard Group Inc. increased its holdings in shares of Cencora by 5.3% during the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after acquiring an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC grew its position in Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank bought a new stake in Cencora during the 2nd quarter valued at $695,215,000. Viking Global Investors LP raised its holdings in Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Amundi raised its holdings in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after buying an additional 249,742 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company raised their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird set a $415.00 price target on Cencora in a research note on Tuesday, January 13th. Barclays started coverage on Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective for the company. Finally, Bank of America dropped their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $393.08.

Cencora Trading Up 0.2%

NYSE COR opened at $353.07 on Friday. The business’s fifty day moving average is $348.49 and its 200-day moving average is $322.06. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The stock has a market capitalization of $68.49 billion, a price-to-earnings ratio of 44.41, a PEG ratio of 1.68 and a beta of 0.66. Cencora, Inc. has a one year low of $237.71 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 20,316 shares of company stock valued at $7,151,265. Company insiders own 10.80% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.